- Patent cliffs and litigation risks remain
- RSV vaccine already a blockbuster
Investors can sometimes be a fickle bunch – a company might put out a perfectly healthy set of results only to see its shares lurch instantly downward.
This was the case when GSK (GSK) released its 2023 figures: consensus-beating revenue growth of 5 per cent (at constant currency) was met by a share price drop of 1 per cent in early trading, although by midday the shares had recovered and were up 3 per cent.